BTIG raised the firm’s price target on Exagen (XGN) to $15 from $13 and keeps a Buy rating on the shares after its Q1 results. The company is driving a solid balance of volume and pricing gains, and is nearing positive adjusted EBITDA, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN:
- Exagen price target raised to $18 from $15 at B. Riley
- Exagen Inc. Reports Strong Q3 2025 Performance
- Exagen’s Earnings Call: Growth Amid Financial Hurdles
- Exagen’s Growth Potential Amid ASP Challenges: A Positive Long-Term Investment Outlook
- Exagen’s Strong Volume Growth and Market Penetration Support Buy Rating Despite Temporary ASP Setbacks